Add to ORKGAuthors ’ disclosures of potential conflicts of interest are found at the end of this article
ton, DC. Published online ahead of print at www.jco.org on December 15, 2014. Authors ’ disclosures ...
The contents of this article are solely the responsibility of the authors and do not necessarily rep...
Authors ' disclosures of potential conflict of interest are found at the end of this article
Authors ’ disclosures of potential conflicts of interest are found at the end of this article
Author's disclosures of potential conflict of interest are found at the end of this article
Bortezomib improves adoptive T cell therapy by sensitizing cancer cells to FasL cytotoxicit
Purpose: We sought to determine the prevalence, reliability, and predictors of conflict of interest ...
Disclosures of potential conflicts of interest may be found at the end of this article
Authors ’ disclosures of potential conflicts of interest are found at the end of this article
Context Disclosure of conflicts of interest (COIs) from pharmaceutical industry study funding and au...
Author’s disclosures of potential conflict of interest are found at the end of this article
Abstract CONTEXT: Disclosure of conflicts of interest (COIs) from pharmaceutical industry study fund...
Disclosures of potential conflicts of interest may be found at the end of this article
Background Disclosure of potential conflicts of interest (CoI) is a standard practice for many biome...
Author’s disclosures of potential conflicts of interest are found at the end of this article. Addres...
ton, DC. Published online ahead of print at www.jco.org on December 15, 2014. Authors ’ disclosures ...
The contents of this article are solely the responsibility of the authors and do not necessarily rep...
Authors ' disclosures of potential conflict of interest are found at the end of this article
Authors ’ disclosures of potential conflicts of interest are found at the end of this article
Author's disclosures of potential conflict of interest are found at the end of this article
Bortezomib improves adoptive T cell therapy by sensitizing cancer cells to FasL cytotoxicit
Purpose: We sought to determine the prevalence, reliability, and predictors of conflict of interest ...
Disclosures of potential conflicts of interest may be found at the end of this article
Authors ’ disclosures of potential conflicts of interest are found at the end of this article
Context Disclosure of conflicts of interest (COIs) from pharmaceutical industry study funding and au...
Author’s disclosures of potential conflict of interest are found at the end of this article
Abstract CONTEXT: Disclosure of conflicts of interest (COIs) from pharmaceutical industry study fund...
Disclosures of potential conflicts of interest may be found at the end of this article
Background Disclosure of potential conflicts of interest (CoI) is a standard practice for many biome...
Author’s disclosures of potential conflicts of interest are found at the end of this article. Addres...
ton, DC. Published online ahead of print at www.jco.org on December 15, 2014. Authors ’ disclosures ...
The contents of this article are solely the responsibility of the authors and do not necessarily rep...
Authors ' disclosures of potential conflict of interest are found at the end of this article